机构:[1]Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, China[2]Department of Endocrinology, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China[3]Department of Physiology and Pathophysiology, Tianjin Medical University, Tianjin, China[4]Central Lab of Binzhou People’s Hospital, Central Lab of Binzhou People’s Hospital, Shandong, China[5]Artemisinin Research Center, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China[6]Jiangsu Key Laboratory of Immunity and Metabolism, Department of Pathogen Biology and Immunology, Xuzhou Medical University, Xuzhou, Jiangsu, China[7]School of Pharmaceutical, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China[8]Department of Hepatobiliary Surgery, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China[9]Guangdong Provincial Institute of Sports Science, Guangzhou, Guangdong, China[10]Division of Hypothalamic Research, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, USA[11]School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China
This work was supported by the National Natural Science Foundation of
China (grant nos. 81800738, 81773969, 81102883, 81800718 and 82070891),
the first-class
discipline construction major project of Guangzhou University of
Chinese Medicine (Guangzhou University of Chinese Medicine Planning (2018,
No. 6), Guangzhou University of Chinese Medicine Planning (2019, No. 5)), the
Guangdong Science and Technology Collaborative Innovation Center for Sport
Science (2019B110210004), the Natural Science Foundation of the Jiangsu Higher
Education Institutions of China (No. 18KJB310015), the Jiangsu Shuangchuang
Programme and the Starting Foundation for Talents of Xuzhou Medical
University (No. D2018006). Shandong key research and development program
(2019GSF108270).
语种:
外文
PubmedID:
中科院(CAS)分区:
出版当年[2020]版:
大类|1 区医学
小类|1 区胃肠肝病学
最新[2025]版:
大类|1 区医学
小类|1 区胃肠肝病学
第一作者:
第一作者机构:[1]Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, China
共同第一作者:
通讯作者:
通讯机构:[1]Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, China[3]Department of Physiology and Pathophysiology, Tianjin Medical University, Tianjin, China[10]Division of Hypothalamic Research, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, USA[11]School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China[*1]Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou 510006, China[*2]Department of Physiology and Pathophysiology, Tianjin Medical University, Tianjin, China[*3]School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, China
推荐引用方式(GB/T 7714):
Sun Nannan,Shen Chuangpeng,Zhang Lei,et al.Hepatic Krüppel-like factor 16 (KLF16) targets PPARα to improve steatohepatitis and insulin resistance.[J].Gut.2021,70(11):2183-2195.doi:10.1136/gutjnl-2020-321774.
APA:
Sun Nannan,Shen Chuangpeng,Zhang Lei,Wu Xiaojie,Yu Yuanyuan...&Gao Yong.(2021).Hepatic Krüppel-like factor 16 (KLF16) targets PPARα to improve steatohepatitis and insulin resistance..Gut,70,(11)
MLA:
Sun Nannan,et al."Hepatic Krüppel-like factor 16 (KLF16) targets PPARα to improve steatohepatitis and insulin resistance.".Gut 70..11(2021):2183-2195